{"entity": "researcher", "timestamp": "2026-08-07T18:35:03.784Z", "family": "Gryb\u00e4ck", "given": "Per", "initials": "P", "orcid": "0000-0002-1141-6234", "affiliations": ["Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden."], "links": {"self": {"href": "https://publications.scilifelab.se/researcher/7b5986c379cd4d23a0b48ac328faab63.json"}, "display": {"href": "https://publications.scilifelab.se/researcher/7b5986c379cd4d23a0b48ac328faab63"}}, "publications": [{"entity": "publication", "iuid": "d28a4f21a24a4775aecb9fff4b468e8a", "links": {"self": {"href": "https://publications.scilifelab.se/publication/d28a4f21a24a4775aecb9fff4b468e8a.json"}, "display": {"href": "https://publications.scilifelab.se/publication/d28a4f21a24a4775aecb9fff4b468e8a"}}, "title": "Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial.", "authors": [{"family": "Matikas", "given": "Alexios", "initials": "A", "orcid": "0000-0002-4122-9624", "researcher": {"href": "https://publications.scilifelab.se/researcher/0af6483a77d746c2b838414692f1f4ed.json"}}, {"family": "Tzoras", "given": "Evangelos", "initials": "E"}, {"family": "Sarafidis", "given": "Michail", "initials": "M"}, {"family": "Sifakis", "given": "Emmanouil G", "initials": "EG", "orcid": "0000-0001-9919-4471", "researcher": {"href": "https://publications.scilifelab.se/researcher/c8506000a14a4a5286aa557ab67ef690.json"}}, {"family": "Bj\u00f6hle", "given": "Judith", "initials": "J"}, {"family": "Barnekow", "given": "Elin", "initials": "E"}, {"family": "Margolin", "given": "Sara", "initials": "S"}, {"family": "Isaksson-Friman", "given": "Erika", "initials": "E"}, {"family": "Kessler", "given": "Luisa Edman", "initials": "LE"}, {"family": "Zouzos", "given": "Athanasios", "initials": "A", "orcid": "0000-0003-2654-827X", "researcher": {"href": "https://publications.scilifelab.se/researcher/776e7ba8993b4465a27451629b509490.json"}}, {"family": "Johansson", "given": "Hemming", "initials": "H"}, {"family": "Hellstr\u00f6m", "given": "Mats", "initials": "M"}, {"family": "Agartz", "given": "Susanne", "initials": "S"}, {"family": "Gryb\u00e4ck", "given": "Per", "initials": "P", "orcid": "0000-0002-1141-6234", "researcher": {"href": "https://publications.scilifelab.se/researcher/7b5986c379cd4d23a0b48ac328faab63.json"}}, {"family": "Salgkamis", "given": "Dimitrios", "initials": "D", "orcid": "0000-0002-3020-0359", "researcher": {"href": "https://publications.scilifelab.se/researcher/826836fefcf5440ebef1c404e046a0ca.json"}}, {"family": "Zerdes", "given": "Ioannis", "initials": "I", "orcid": "0000-0002-8304-2462", "researcher": {"href": "https://publications.scilifelab.se/researcher/f786763a4a0e4b5bb865ebb199eb6ca2.json"}}, {"family": "Wang", "given": "Kang", "initials": "K", "orcid": "0000-0001-5401-1803", "researcher": {"href": "https://publications.scilifelab.se/researcher/7bdb074014224910b0f34e893b15e660.json"}}, {"family": "Hartman", "given": "Johan", "initials": "J", "orcid": "0000-0002-6500-8527", "researcher": {"href": "https://publications.scilifelab.se/researcher/da7cefda6e00463d8ba95fc63eeb8f0a.json"}}, {"family": "Acs", "given": "Balazs", "initials": "B", "orcid": "0000-0002-0972-4633", "researcher": {"href": "https://publications.scilifelab.se/researcher/efe428be3caf4deca0a7839d555f6c33.json"}}, {"family": "Sun", "given": "Wenwen", "initials": "W"}, {"family": "Boyaci", "given": "Ceren", "initials": "C"}, {"family": "Villacampa", "given": "Guillermo", "initials": "G"}, {"family": "Pascual", "given": "Tomas", "initials": "T", "orcid": "0000-0001-8431-3183", "researcher": {"href": "https://publications.scilifelab.se/researcher/c10a027f0fa74b6b9a667edcadf8f50e.json"}}, {"family": "Gavila", "given": "Joaquin", "initials": "J"}, {"family": "Prat", "given": "Aleix", "initials": "A", "orcid": "0000-0003-2377-540X", "researcher": {"href": "https://publications.scilifelab.se/researcher/582dfbb079214acbb35af0a0590b2fb3.json"}}, {"family": "Perou", "given": "Charles", "initials": "C"}, {"family": "Brandberg", "given": "Yvonne", "initials": "Y"}, {"family": "Bergh", "given": "Jonas", "initials": "J", "orcid": "0000-0001-5526-1847", "researcher": {"href": "https://publications.scilifelab.se/researcher/fd38f4f7704144ed9e3f869e197175e6.json"}}, {"family": "Hatschek", "given": "Thomas", "initials": "T"}, {"family": "Foukakis", "given": "Theodoros", "initials": "T", "orcid": "0000-0001-8952-9987", "researcher": {"href": "https://publications.scilifelab.se/researcher/7683c0280e9b4145aa54305fb08936a7.json"}}], "type": "journal article", "published": "2026-04-08", "journal": {"title": "Nat Commun", "issn": "2041-1723", "volume": "17", "issue": "1", "issn-l": "2041-1723"}, "abstract": "In PREDIX LumB patients with estrogen receptor positive and human epidermal growth factor receptor negative (ER + /HER2-) breast cancer > 20 mm and/or with lymph node metastasis were randomized 1:1 to receive either paclitaxel weekly for 12 weeks followed by palbociclib and endocrine therapy for 12 weeks (arm A), or the reverse sequence (arm B). Primary endpoint is objective radiologic response at 12 weeks (ORR12), and key secondary endpoints are ORR24, pathologic complete response, event-free survival, safety and correlative studies of tissue and circulating biomarkers. Whole exome sequencing and RNA sequencing were performed on baseline fresh frozen tissue samples. In total, 179 patients comprise the intention-to-treat population. There is no statistically significant difference between the two arms in ORR12 (59% vs 45%, p = 0.058). An exploratory gene expression analysis identified differentially expressed genes and gene sets between responders and non-responders at 12 weeks. A predictive signature, CDKPredX, comprising 31 genes related to proliferation, ER signaling and immune activity was developed to identify patients resistant to chemotherapy but responding to palbociclib plus endocrine therapy (pinteraction=0.03). The predictive signature was independently validated in the CORALLEEN trial (pinteraction=0.048). Clinicaltrials.gov identifier: NCT02603679.", "doi": "10.1038/s41467-026-71452-6", "pmid": "41951647", "labels": {"NGI Short read": "Service", "NGI Uppsala (SNP&SEQ Technology Platform)": "Service", "National Genomics Infrastructure": "Service"}, "xrefs": [{"db": "pii", "key": "10.1038/s41467-026-71452-6"}, {"db": "pmc", "key": "PMC13069018"}, {"db": "ClinicalTrials.gov", "key": "NCT02603679"}], "notes": [], "created": "2026-04-13T07:03:30.099Z", "modified": "2026-04-13T07:03:31.324Z"}, {"entity": "publication", "iuid": "3b7694b30bde4b54958fd548cc57a848", "links": {"self": {"href": "https://publications.scilifelab.se/publication/3b7694b30bde4b54958fd548cc57a848.json"}, "display": {"href": "https://publications.scilifelab.se/publication/3b7694b30bde4b54958fd548cc57a848"}}, "title": "Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial.", "authors": [{"family": "Matikas", "given": "Alexios", "initials": "A", "orcid": "0000-0002-4122-9624", "researcher": {"href": "https://publications.scilifelab.se/researcher/0af6483a77d746c2b838414692f1f4ed.json"}}, {"family": "Johansson", "given": "Hemming", "initials": "H", "orcid": "0000-0002-7156-1468", "researcher": {"href": "https://publications.scilifelab.se/researcher/adc6a3286c5446aeb1bcc0e63520b321.json"}}, {"family": "Gryb\u00e4ck", "given": "Per", "initials": "P", "orcid": "0000-0002-1141-6234", "researcher": {"href": "https://publications.scilifelab.se/researcher/7b5986c379cd4d23a0b48ac328faab63.json"}}, {"family": "Bj\u00f6hle", "given": "Judith", "initials": "J", "orcid": "0000-0002-1902-4032", "researcher": {"href": "https://publications.scilifelab.se/researcher/b3ed84a3e1174cacbea92a02eda8d64c.json"}}, {"family": "Acs", "given": "Balazs", "initials": "B", "orcid": "0000-0002-0972-4633", "researcher": {"href": "https://publications.scilifelab.se/researcher/efe428be3caf4deca0a7839d555f6c33.json"}}, {"family": "Boyaci", "given": "Ceren", "initials": "C", "orcid": "0000-0001-5598-0243", "researcher": {"href": "https://publications.scilifelab.se/researcher/d1a803107a224c578bf01ef65aba69ff.json"}}, {"family": "Lekberg", "given": "Tobias", "initials": "T", "orcid": "0000-0002-0467-9386", "researcher": {"href": "https://publications.scilifelab.se/researcher/82b08d5e558c4638a5b16f57bf0bf0e3.json"}}, {"family": "Fredholm", "given": "Hanna", "initials": "H", "orcid": "0000-0002-2136-6162", "researcher": {"href": "https://publications.scilifelab.se/researcher/339374f722bb4509b00dddc99f76f2a2.json"}}, {"family": "Elinder", "given": "Ellinor", "initials": "E", "orcid": "0000-0001-8596-5327", "researcher": {"href": "https://publications.scilifelab.se/researcher/4ad9790c06fe4f4d95aace0e5a88d484.json"}}, {"family": "Margolin", "given": "Sara", "initials": "S", "orcid": "0000-0002-5526-5570", "researcher": {"href": "https://publications.scilifelab.se/researcher/c4a4c163089c4f4f93bdf41901cf479f.json"}}, {"family": "Isaksson-Friman", "given": "Erika", "initials": "E", "orcid": "0000-0001-8055-4297", "researcher": {"href": "https://publications.scilifelab.se/researcher/7d492b7da469447c96a0ad71e701e0dd.json"}}, {"family": "Bosch", "given": "Ana", "initials": "A", "orcid": "0000-0003-0666-5946", "researcher": {"href": "https://publications.scilifelab.se/researcher/e47d3af612294c9c9534dfa3586f2531.json"}}, {"family": "Lindman", "given": "Henrik", "initials": "H", "orcid": "0000-0002-5871-268X", "researcher": {"href": "https://publications.scilifelab.se/researcher/49c5d63f995546049a240cd52052e1df.json"}}, {"family": "Adra", "given": "Jamila", "initials": "J", "orcid": "0000-0001-6361-661X", "researcher": {"href": "https://publications.scilifelab.se/researcher/6c375ff5c4b540059682de096d94c20d.json"}}, {"family": "Andersson", "given": "Anne", "initials": "A", "orcid": "0000-0002-9597-6465", "researcher": {"href": "https://publications.scilifelab.se/researcher/67f8d63302ec42b3aa7b758b9a999e24.json"}}, {"family": "Agartz", "given": "Susanne", "initials": "S", "orcid": "0000-0002-1895-2515", "researcher": {"href": "https://publications.scilifelab.se/researcher/c097cacc53e14e62a480fa6da19abf0b.json"}}, {"family": "Hellstr\u00f6m", "given": "Mats", "initials": "M", "orcid": "0000-0001-7897-4006", "researcher": {"href": "https://publications.scilifelab.se/researcher/35b4a647e2994968b06152e8ab8bca81.json"}}, {"family": "Zerdes", "given": "Ioannis", "initials": "I", "orcid": "0000-0002-8304-2462", "researcher": {"href": "https://publications.scilifelab.se/researcher/f786763a4a0e4b5bb865ebb199eb6ca2.json"}}, {"family": "Hartman", "given": "Johan", "initials": "J", "orcid": "0000-0002-6500-8527", "researcher": {"href": "https://publications.scilifelab.se/researcher/da7cefda6e00463d8ba95fc63eeb8f0a.json"}}, {"family": "Bergh", "given": "Jonas", "initials": "J", "orcid": "0000-0001-5526-1847", "researcher": {"href": "https://publications.scilifelab.se/researcher/fd38f4f7704144ed9e3f869e197175e6.json"}}, {"family": "Hatschek", "given": "Thomas", "initials": "T", "orcid": "0000-0003-3067-2492", "researcher": {"href": "https://publications.scilifelab.se/researcher/92a10c95c77a4d4eb6328c1704056ea3.json"}}, {"family": "Foukakis", "given": "Theodoros", "initials": "T", "orcid": "0000-0001-8952-9987", "researcher": {"href": "https://publications.scilifelab.se/researcher/7683c0280e9b4145aa54305fb08936a7.json"}}], "type": "clinical trial, phase ii", "published": "2023-02-01", "journal": {"title": "Clin. Cancer Res.", "issn": "1557-3265", "volume": "29", "issue": "3", "pages": "532-540", "issn-l": "1078-0432"}, "abstract": "PREDIX HER2 is a randomized Phase II trial that compared neoadjuvant docetaxel, trastuzumab, and pertuzumab (THP) with trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Rates of pathologic complete response (pCR) did not differ between the two groups. Here, we present the survival outcomes from PREDIX HER2 and investigate metabolic response and tumor-infiltrating lymphocytes (TIL) as prognostic factors.\n\nIn total, 202 patients with HER2-positive breast cancer were enrolled and 197 patients received six cycles of either THP or T-DM1. Secondary endpoints included event-free survival (EFS), recurrence-free survival (RFS), and overall survival (OS). Assessment with PET/CT was performed at baseline, after two and six treatment cycles. TILs were assessed manually at baseline biopsies, while image-based evaluation of TILs [digital TILs (DTIL)] was performed in digitized full-face sections.\n\nAfter a median follow-up of 5.21 years, there was no difference between the two treatment groups in terms of EFS [HR = 1.26; 95% confidence interval (CI), 0.54-2.91], RFS (HR = 0.69; 95% CI, 0.24-1.93), or OS (HR = 0.52; 95% CI, 0.09-2.82). Higher SUVmax at cycle 2 (C2) predicted lower pCR (ORadj = 0.65; 95% CI, 0.48-0.87; P = 0.005) and worse EFS (HRadj = 1.27; 95% CI, 1.12-1.41; P < 0.001). Baseline TILs and DTILs provided additional prognostic information to clinical parameters and C2 SUVmax.\n\nLong-term outcomes following neoadjuvant T-DM1 were similar to neoadjuvant THP. SUVmax after two cycles of neoadjuvant therapy for HER2-positive breast cancer may be an independent predictor of both short- and long-term outcomes. Combined assessment with TILs may facilitate early selection of poor responders for alternative treatment strategies.", "doi": "10.1158/1078-0432.CCR-22-2829", "pmid": "36449695", "labels": {"Bioinformatics Support for Computational Resources": "Service"}, "xrefs": [{"db": "pii", "key": "711355"}, {"db": "ClinicalTrials.gov", "key": "NCT02568839"}, {"db": "EudraCT", "key": "2014-000808-10"}], "notes": [], "created": "2023-11-27T21:58:15.413Z", "modified": "2024-01-16T13:48:33.993Z"}]}